Biogen partner Eisai cut US jobs. Now can it boost Alzheimer's drug sales? / Sage Therapeutics Jumps on Biogen's $469 Million Takeover Offer / European drug regulator rejects Alzheimer's treatment Leqembi from Biogen, Eisai / Stocks making the biggest moves midday: JetBlue Airways, Shopify, Biogen and more / Biogen revenue and profit shrink on Aduhelm costs, slumping sales of multiple sclerosis therapies / Biogen to stop selling controversial Alzheimer's drug Aduhelm / Biogen drops controversial Alzheimer's drug Aduhelm to focus on Leqembi, experimental treatments / Biogen Quits Controversial Alzheimer's Drug Aduhelm / Biogen scraps controversial Alzheimer's drug Aduhelm / Biogen to cease production of controversial Alzheimer's drug